TG-46 (TG46) inhibits JAK2, FLT3, RET, JAK3 and can be used to study glaucoma.

TG 100572 Hydrochloride is a inhibitor of multi-targeted kinase which inhibits receptor tyrosine kinases and Src kinases(IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively).

TG 100801 is a dual inhibitor of VEGFr2 and Src family (Src and YES) kinases and is a candidate compound for the treatment of age-related macular degeneration (AMD).

TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian and cervical cancer.

TG 100713 is a pan-PI3K inhibitor against PI3Kγ, PI3Kδ, PI3Kα and PI3Kβ with IC50 of 50 nM, 24 nM, 165 nM and 215 nM, respectively.

TG2-179-1 is a BRCA1-associated protein 1 (BAP1) inhibitor that effectively hampers BAP1's deubiquitinase activity in cell-free assays at concentrations between 25 µM and 1.5 mM. This compound exhibits cytotoxicity towards a range of eight colon cancer cell lines, with half-maximal inhibitory concentrations (IC50s) spanning from 4.48 to 7.52 µM. Additionally, in an HCT116 colon cancer mouse xenograft model, TG2-179-1 administration at doses of 10 and 30 mg/kg significantly reduces tumor volume, demonstrating its potential in vivo efficacy against colon cancer.

TG11-77 HCl is a novel, Potent, Selective, Water Soluble, Brain-Permeable EP2 Receptor Antagonist. TG11-77 HCl has a Schild KB of 9.7 nM on EP2, a water solubility of 2.5 mM, a brain-to-plasma ratio of 0.4, and a plasma half-life of 2.4 h in mice. TG11-77 HCl are representative second generation EP2 antagonists with improved pharmacodynamic and pharmacokinetic properties.

TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM.

TG11-77 free base is a novel, Potent, Selective, Water Soluble, Brain-Permeable EP2 Receptor Antagonist. TG11-77 free base has a Schild KB of 9.7 nM on EP2, a water solubility of 2.5 mM, a brain-to-plasma ratio of 0.4, and a plasma half-life of 2.4 h in mice. TG11-77 free base are representative second generation EP2 antagonists with improved pharmacodynamic and pharmacokinetic properties.

TG11-77 hydrochloride is a potent, selective, and water-soluble EP2 receptor antagonist that is brain-permeable, demonstrating a KB value of 9.7 nM.

HAT-SIL-TG-1&AT, a hypoxia-activated prodrug, functions as a Janus tyrosine kinase (JAK) inhibitor demonstrating antitumor effects by inhibiting JAK-STAT signaling within tumor tissues. It also suppresses the proliferation of HEL cells and downregulates phosphorylated STAT3/5 in hypoxic conditions.

TG-2-IN-1 (Compound D003) is a transglutaminase-2 ( TGM-2 ) inhibitor. TG-2-IN-1 can be used in myopia research[1].

TG6-10-1 is an EP2 antagonist.

AA9 is a novel transglutaminase (TG2) inhibitor.

TG4-155 is a brain penetrant EP2 antagonist (KB = 2.4 nM) that is over 1000-fold less effective at EP4 (KB = 11.4 µM) and a panel of other receptors and channels

PROTAC TG2 Degrader-1 (Compound 11) is a VHL-based PROTAC that targets tissue transglutaminase (TG2) and exhibits a binding affinity with a K D of 68.9 μM. This compound effectively decreases TG2 levels in ovarian cancer cells through a proteasome-dependent pathway [1].

VA4 is a novel irreversible TG2 transamidase site-specific inhibitor.

TG100-115 is a PI3Kγ/δ inhibitor (IC50: 83/235 nM), with fewer effects on PI3Kα/β.

TG003, a potent inhibitor of Clk1/Sty, exhibits inhibitory activity against Clk1 and Clk4 with IC50 values of 20 nM and 15 nM, respectively [1].

TG693, an orally available inhibitor of CLK1, promotes the skipping of the endogenous mutated exon 31 in Duchenne muscular dystrophy (DMD) patient-derived cells and increased the production of the functional exon 31-skipped dystrophin protein.

PROTAC TG2 degrader-2 (compound 7) is a selective competitive degrader of Transglutaminase 2 (TG2), exhibiting a dissociation constant (Kd) greater than 100 μM. It inhibits cell migration and reduces TG2 levels in ovarian cancer cells, making it a valuable tool for ovarian cancer research [1].

(E/Z)-TG003 is a potent and ATP-competitive Cdc2-like kinase (Clk) inhibitor.

TG2-IN-3h is a highly selective, potent, cell-permeable fluorescent irreversible tissue transglutaminase (tg2) inhibitor

TG100948 is a novel dual VEGFR/Src kinase inhibitor.

TG6-129 is an antagonist of the EP2 receptor. TG6-129 suppresses PGE2-induced elevation of cAMP in cells expressing EP2 with an IC50 value of 1.6 µM. TG6-129 reduces the expression of COX-2, IL-1β, IL-6, IL-12, IL-23 and TNF-α induced by the EP2-selective